Credit rating agency, CARE has reaffirmed ‘AA-’ rating to Wockhardt’s long term bank facilities worth Rs 295 crore and ‘A1+’ rating to company’s Short term Bank Facilities worth Rs 222.50 crore.
The company has received the ratings on the back of its and well-established presence in the global pharmaceutical industry, its well-diversified product portfolio having established brands catering to multiple therapeutic segments and accredited manufacturing facilities supported with well equipped R&D facilities mainly in complex generics.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
